ALS-PDC1
MCID: AMY027
MIFTS: 38

Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 (ALS-PDC1)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

MalaCards integrated aliases for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1:

Name: Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 56 12 52 73 29
Guam Disease 56 12 52 58 73
Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex of Guam 56 12 73
Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex, Susceptibility to 56 13
Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia of Guam Syndrome 12 58
Parkinsonism-Dementia-Als Complex 12 58
Parkinsonian Disorders 43 71
Lytico-Bodig Disease 12 58
Als-Pdc 56 12
Pdals 12 58
Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1, Susceptibility to 6
Amyotrophic Lateral Sclerosis, Parkinsonism/dementia Complex of Guam 52
Sclerosis, Lateral, Amyotrophic/parkinsonism/dementia Complex 1 39
Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 56
Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 58
Amyotrophic Lateral Sclerosis, Guam Form 71
Als/pdc of Guam 73
Als-Pdc1 73

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
amyotrophic lateral sclerosis-parkinsonism/dementia complex 1:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:0111246
OMIM 56 105500
ICD10 via Orphanet 33 G12.2
UMLS via Orphanet 72 C0543859
Orphanet 58 ORPHA90020
MedGen 41 C0543859
UMLS 71 C0242422 C0543859

Summaries for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

OMIM : 56 Amyotrophic lateral sclerosis-parkinsonism/dementia complex of Guam is a neurodegenerative disorder with unusually high incidence among the Chamorro people of Guam. Both ALS and parkinsonism-dementia are chronic, progressive, and uniformly fatal disorders in this population. Both diseases are known to occur in the same kindred, the same sibship, and even the same individual. (105500)

MalaCards based summary : Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1, also known as guam disease, is related to dementia and rare genetic parkinsonian disorder, and has symptoms including tremor, abnormality of extrapyramidal motor function and bradykinesia. An important gene associated with Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 is TRPM7 (Transient Receptor Potential Cation Channel Subfamily M Member 7). The drugs Zonisamide and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and skin, and related phenotypes are muscle weakness and amyotrophic lateral sclerosis

Disease Ontology : 12 A neurodegenerative disease characterized by chronic, progressive amyotrophic lateral sclerosis and parkinsonism-dementia. Susceptibility to this disease is influenced by heterozygous mutation in TRPM7 on 15q21.2.

UniProtKB/Swiss-Prot : 73 Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1: A neurodegenerative disorder characterized by chronic, progressive and uniformly fatal amyotrophic lateral sclerosis and parkinsonism- dementia. Both diseases are known to occur in the same kindred, the same sibship and even the same individual.

Related Diseases for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Diseases related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 dementia 29.0 TRPM7 PCSK1N PARK7
2 rare genetic parkinsonian disorder 12.3
3 rare parkinsonian disorder 12.3
4 parkinson disease 7, autosomal recessive early-onset 11.2
5 amyotrophic lateral sclerosis 1 10.9
6 lateral sclerosis 10.9
7 multiple system atrophy 1 10.7
8 alzheimer disease 10.6
9 supranuclear palsy, progressive, 1 10.6
10 parkinson disease, late-onset 10.4
11 ophthalmomyiasis 10.4
12 corticobasal degeneration 10.4
13 pick disease of brain 10.3
14 amnestic disorder 10.3
15 mutism 10.3
16 akinetic mutism 10.3
17 tremor 10.3
18 movement disease 10.3
19 multiple system atrophy, parkinsonian type 10.3
20 motor neuron disease 10.2
21 rem sleep behavior disorder 10.2
22 autonomic dysfunction 10.1
23 frontotemporal dementia 10.1
24 apraxia 10.0
25 pure autonomic failure 10.0
26 dementia, lewy body 10.0
27 huntington disease 10.0
28 striatonigral degeneration 10.0
29 dystonia 10.0
30 pseudobulbar affect 10.0
31 cerebral amyloid angiopathy, cst3-related 9.8
32 palmomental reflex 9.8
33 schopf-schulz-passarge syndrome 9.8
34 ataxia and polyneuropathy, adult-onset 9.8
35 autoimmune lymphoproliferative syndrome 9.8
36 orthostatic intolerance 9.8
37 psoriatic arthritis 9.8
38 anxiety 9.8
39 parkinsonism-dystonia, infantile, 2 9.8
40 aspiration pneumonia 9.8
41 focal dystonia 9.8
42 scoliosis 9.8
43 hemosiderosis 9.8
44 olivopontocerebellar atrophy 9.8
45 ideomotor apraxia 9.8
46 essential tremor 9.8
47 blepharospasm 9.8
48 sleep disorder 9.8
49 neuroblastoma 9.8
50 alien hand syndrome 9.8

Graphical network of the top 20 diseases related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1:



Diseases related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Symptoms & Phenotypes for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Human phenotypes related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1:

31 (show all 8)
# Description HPO Frequency HPO Source Accession
1 muscle weakness 31 HP:0001324
2 amyotrophic lateral sclerosis 31 HP:0007354
3 paralysis 31 HP:0003470
4 dementia 31 HP:0000726
5 parkinsonism 31 HP:0001300
6 bulbar palsy 31 HP:0001283
7 abnormal lower motor neuron morphology 31 HP:0002366
8 muscle spasm 31 HP:0003394

Symptoms via clinical synopsis from OMIM:

56
Muscle:
muscle weakness
muscle cramps

Misc:
chronic, progressive, and fatal

Neuro:
amyotrophic lateral sclerosis
parkinsonism-dementia
progressive motor function loss
lower motor neuron manifestations
bulbar paralysis

Clinical features from OMIM:

105500

UMLS symptoms related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1:


tremor, abnormality of extrapyramidal motor function, bradykinesia, symptoms, central nervous system signs and symptoms

Drugs & Therapeutics for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Drugs for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Amantadine Approved Phase 4 768-94-5 2130
4
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
7
Iodine Approved, Investigational Phase 4 7553-56-2 807
8
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
9
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
10 Calcium, Dietary Phase 4
11 calcium channel blockers Phase 4
12 Dopamine Agents Phase 4
13 Antiparkinson Agents Phase 4
14 Anti-Infective Agents Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Antiviral Agents Phase 4
17 Analgesics Phase 4
18 Autonomic Agents Phase 4
19 Whey Protein Phase 4
20 Gastrointestinal Agents Phase 4
21 Soy Bean Phase 4
22 Antidepressive Agents Phase 4
23 Quetiapine Fumarate Phase 4 111974-72-2
24 Serotonin Uptake Inhibitors Phase 4
25 Antiemetics Phase 4
26 Serotonin Agents Phase 4
27 Dopamine Antagonists Phase 4
28 Serotonin Antagonists Phase 4
29 Neurotransmitter Agents Phase 4
30 Tranquilizing Agents Phase 4
31 Psychotropic Drugs Phase 4
32 Central Nervous System Depressants Phase 4
33 Antipsychotic Agents Phase 4
34 Cholinergic Agents Phase 4
35 Nicotinic Agonists Phase 4
36 Pharmaceutical Solutions Phase 4
37 Calamus Phase 4
38 cadexomer iodine Phase 4
39
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
40
Tetrabenazine Approved, Investigational Phase 3 58-46-8 6018
41
Carbon monoxide Approved, Investigational Phase 3 630-08-0 281
42 Antimetabolites Phase 3
43 Adrenergic Agents Phase 3
44
tannic acid Approved Phase 2 1401-55-4
45
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
46
Clonazepam Approved, Illicit Phase 2 1622-61-3 2802
47
Sodium citrate Approved, Investigational Phase 2 68-04-2
48
Caffeine Approved Phase 2 58-08-2 2519
49
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-20-8, 91374-21-9 5095 497540
50
Droxidopa Approved, Investigational Phase 2 23651-95-8 443940

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease Unknown status NCT03034538 Phase 4 Zonegran;Zonegran
2 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function Completed NCT01662414 Phase 4
3 A Multicentre, Randomised, Open Label, Comparative Phase 4 Trial to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism in a General Neurologist Setting. Completed NCT00382967 Phase 4
4 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
5 A Randomized Controlled Trial Study of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism Completed NCT00331825 Phase 4 Risperidone and Olanzapine
6 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
7 A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease Recruiting NCT03034564 Phase 4 Northera;Placebo Oral Tablet
8 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Recruiting NCT03495024 Phase 4 Varenicline
9 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
10 Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication Unknown status NCT02138864 Phase 3
11 An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis Completed NCT01550484 Phase 2, Phase 3 18F-AV-133
12 Novel Neuroimage Study in Tauopathies With Parkinsonism Unknown status NCT03386669 Phase 2 F-18
13 An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Completed NCT01491932 Phase 2 AFQ056
14 12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease Completed NCT01385592 Phase 2 AFQ056;Placebo
15 13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease Completed NCT01491529 Phase 2 AFQ056;Placebo
16 Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism: a Prospective, Randomized, Double-blind and Placebo-controlled Trial Completed NCT02312908 Phase 2 Clonazepam;Placebo
17 The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ) Completed NCT01824056 Phase 2 18F-FDG
18 Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET Completed NCT02059733 Phase 2 18F-DTBZ
19 18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism: Investigating the Correlation Between Cerebral Structural and Functional Changes, and Clinical Manifestation Completed NCT02195154 Phase 2 18F-DTBZ
20 Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism Completed NCT01653132 Phase 2 Incobotulinum Toxin A;Placebo
21 From Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism Completed NCT01759888 Phase 2 18F-DTBZ
22 Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study. Completed NCT01190735 Phase 2 Caffeine alkaloid
23 An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa Recruiting NCT03250117 Phase 1, Phase 2 Ropinirole oral product;Ropinirole Implant
24 Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease Recruiting NCT01860794 Phase 1, Phase 2 Mesencephalic Neuronal Precursor Cells
25 Effect of Exercise on Recovery in Drug-Induced Parkinsonism and Parkinson Disease Recruiting NCT02598973 Phase 1, Phase 2
26 Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Not yet recruiting NCT03446807 Phase 2 Droxidopa;Placebo Oral Tablet
27 A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders Terminated NCT00686699 Phase 2 Preladenant;Placebo
28 Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease Terminated NCT00643890 Phase 2
29 Does Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism? Withdrawn NCT00472355 Phase 2 apomorphine
30 Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) Withdrawn NCT01565395 Phase 2 Incobotulinum Toxin A;placebo
31 Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease Unknown status NCT00673140 Phase 1
32 Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Unknown status NCT00767546 Phase 1 Botulinum toxin
33 Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients Completed NCT00845000 Phase 1 SCH 420814 10 mg;SCH 420814 100 mg;Placebo;Levodopa;Carbidopa
34 A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies Completed NCT01056965 Phase 1 davunetide (AL-108, NAP);Placebo nasal spray
35 A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease Recruiting NCT04075318 Phase 1
36 An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa Active, not recruiting NCT03065192 Phase 1 VY-AADC01
37 The Efficacy of Long-term Whole-body Vibration in the Treatment of Parkinson's Disease Unknown status NCT02306863
38 Changes of the Neuronal Activity in the Subthalamic Nucleus Under Propofol Sedation During Stereotactic Electrode Implantation. Unknown status NCT00355927
39 Observational Study Assessing the Diagnostic Contribution of 3-Tesla MRI, CSF Analysis and a Second Opinion in a Specialized Movement Disorder Centre, in Differentiating Between Parkinson's Disease and Atypical Parkinsonism Unknown status NCT01249768
40 Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy. Unknown status NCT01380899
41 BEWARE: Body Awareness Training in the trEatment of Wearing-off Related Anxiety in Patients With paRkinson's diseasE. Unknown status NCT02054845
42 Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) Unknown status NCT02696603
43 Repetitive Transcranial Magnetic Stimulation for Freezing of Gait Completed NCT01853150
44 The Association of Neurotoxin Exposure With Parkinson's Disease and Parkinsonism in World War II Veterans and Other Men Completed NCT00018577
45 Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System. Completed NCT01246336
46 A Whey Protein-based Nutritional Supplement Enriched in Vitamin D, Leucine and Calcium for Patients With Parkinsonism Undergoing Rehabilitation Treatment: a Randomized Trial Completed NCT03124277
47 Distribution of Non-Motor Symptoms in Idiopathic Parkinson's Disease and Secondary Parkinsonism A Controlled, Descriptive Cross-sectional Study Using Parkinson's Well-Being Map™ Completed NCT03432338
48 Statistical Mapping of the Brain in Progressive Supranuclear Palsy, Essential Tremor, Parkinson Disease, Parkinsonism, and REM Behavior Disorder Completed NCT01547481
49 A Randomized Open Labelled Placebo Controlled Trial to Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism Completed NCT02265484 Lactulose+Rifaximin +Bromocriptine
50 Increasing Mobility in Parkinsonian Patients With Freezing of Gait and Gait Hypokinesia With an Adjustable, Attachable Laser (Mobilaser) Completed NCT01581645 Early Phase 1

Search NIH Clinical Center for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Procyclidine
Procyclidine hydrochloride

Cochrane evidence based reviews: parkinsonian disorders

Genetic Tests for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Genetic tests related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1:

# Genetic test Affiliating Genes
1 Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 29 TRPM7

Anatomical Context for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

MalaCards organs/tissues related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1:

40
Brain, Subthalamic Nucleus, Skin, Thalamus, Testes

Publications for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Articles related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1:

(show all 27)
# Title Authors PMID Year
1
TRPM7 is not associated with amyotrophic lateral sclerosis-parkinsonism dementia complex in the Kii peninsula of Japan. 56 6
19405049 2010
2
A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders. 56 6
16051700 2005
3
Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. 61 56
3603037 1987
4
C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. 56
22637429 2012
5
Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. 56
19567404 2009
6
The ALS/PDC syndrome of Guam and the cycad hypothesis. 56
18490618 2008
7
Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE. 56
17515539 2007
8
Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. 56
17185385 2007
9
Debating the cause of a neurological disorder. 56
16990532 2006
10
TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of Guam. 56
11708997 2001
11
Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis. 56
11310628 2001
12
A missense mutation in the SOD1 gene in patients with amyotrophic lateral sclerosis from the Kii Peninsula and its vicinity, Japan. 56
10732812 1997
13
Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. 56
7936240 1994
14
Guam: deadly disease dying out. 56
8332906 1993
15
Potential role of an additive genetic component in the cause of amyotrophic lateral sclerosis and parkinsonism-dementia in the western Pacific. 56
8418664 1993
16
Patterns of acquiring parkinsonism-dementia complex on Guam. 1944 through 1985. 56
2396931 1990
17
Amyloid of neurofibrillary tangles of Guamanian parkinsonism-dementia and Alzheimer disease share identical amino acid sequence. 56
3470778 1987
18
Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. 56
3969206 1985
19
Blood groups, immunoglobulin allotypes and dermatoglyphic features of patients with amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. 56
6573136 1983
20
Search for a red cell enzyme or serum protein marker in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. 56
6573137 1983
21
Amyotrophic lateral sclerosis among Chamorro migrants from Guam. 56
7212649 1980
22
Amyotrophic lateral sclerosis-Parkinsonism dementia complex of Guam: further genetic investigations. 56
5770171 1969
23
Parkinsonism-dementia complex, an endemic disease on the island of Guam. I. Clinical features. 56
13907609 1961
24
Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). 61
18843496 2008
25
[Role of excitatory amino acids in neuropathology]. 61
8728878 1995
26
l-BMAA and kainate-induced modulation of neurofilament concentrations as a measure of neurite outgrowth: Implications for an in vitro test of neurotoxicity. 61
20732212 1993
27
Use of neurite outgrowth as an in vitro method of assessing neurotoxicity. 61
8512188 1993

Variations for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

ClinVar genetic disease variations for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TRPM7 NM_017672.6(TRPM7):c.4445C>T (p.Thr1482Ile)SNV risk factor 4807 rs8042919 15:50878630-50878630 15:50586433-50586433

Expression for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Search GEO for disease gene expression data for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1.

Pathways for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

GO Terms for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

Molecular functions related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.62 PCSK1N PARK7

Sources for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....